HAVCR2 and cancer: Although no dramatic therapeutic effects were observed with the use of these antibodies, the impact of combined therapy (anti-TIM-3 and anti-PD-1) is significantly better than that of separate agents for cancer treatment in the carcinogen induction model (85).